ClinicalTrials.gg
Enrolling by invitationNCT04190758GOTHAUpdated Oct 12, 2021

GOTHA - The Early Arthritis and Psoriasis Study of Region Västra Götaland, Sweden

An observational study in Rheumatoid Arthritis, Psoriatic Arthritis and Arthritis, sponsored by Vastra Gotaland Region. Enrolling by invitation at 1 site in Sweden. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-12.

Sponsored by Vastra Gotaland Region · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,100
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region — 2 open to participants now, 5 under way, none of them phase 3. Arthritis, Rheumatoid · Vastra Gotaland Region.

Started
2020
with 2 others
Observational
5 of 11
1 open now
Registered
7th of 11
by date

Among the 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region, this one is one of 3 that started in 2020, is one of 5 observational ones, and was the 7th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region, or all of them as a file.
02

Study summary

GÖTHA- The early arthritis and psoriasis study of Region Västra Götaland, Sweden - is a longitudinal observational study, which will prospectively and in parallel follow patients with newly diagnosed rheumatoid arthritis (RA, N=1000), psoriatic arthritis (PsA, N=500) and undifferentiated arthritis (N=100), together with patients with psoriasis (N=500). The study will also recruit healthy controls from the general population (N=3000).

The aims of the study are to define predictors for disease course and severity, treatment response, comorbidities, health related quality of life (HRQoL) and health economy.

The study is a collaboration between the department of Rheumatology and the department of Dermatology at Sahlgrenska University Hospital in Gothenburg, and the departments of Rheumatology at the hospitals of Alingsås, Borås, Uddevalla and Skövde, in the west of Sweden.

All patients with newly diagnosed RA, PsA and undifferentiated arthritis at the Rheumatology centers are eligible for inclusion. Patients with psoriasis will be recruited from the Department of dermatology at Sahlgrenska University Hospital.

The patients will be examined at baseline and at one, three, five and ten years. The assessments will include physical examination with evaluation of joints, entheses and skin and validated questionnaires regarding medical history, comorbidities, lifestyle, disease activity, bodily function, socioeconomic factors and HRQoL. Blood samples will be collected. The patients with arthritis will also undergo radiography of the lung, hands and feet, and Cone Beam Computed Tomography (CBCT) of hands and feet.

03

Conditions studied

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Arthritis
  • Psoriasis
  • Cardiovascular Diseases
  • Obesity
  • Lung Diseases
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All patients at any of the involved rheumatology clinics with newly diagnosed RA, PsA or undifferentiated arthritis meeting the study criteria are eligible for inclusion.

Consecutive sampling

Patients with psoriasis diagnosed at a dermatology clinic. Consecutive sampling

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with rheumatoid arthritis (RA) meeting the classification criteria of American College of Rheumatology (ACR) and/or European League Against Rheumatism (EULAR) från 2010
  • Patients with psoriatic arthritis (PsA) meeting the classification criteria of Classification for Psoriatic Arthritis (CASPAR) PsA
  • Patients with undifferentiated arthritis defined as a patients with a clear arthritis, but not meeting with established classifications criteria of any now known rheumatic disease
  • Patients with psoriasis diagnosed at a dermatology department. The patients should not have any history of joint complaints with a duration of more than 6 weeks
  • General population controls, matched for age, sex and residence of living to the included patients.

Exclusion criteria

Exclusion Criteria:

  • Inability to follow study protocol
  • Swedish language difficulties
  • Having other concomitant rheumatic diagnose (Sjögrens syndrome is not an exclusion criteria)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with rheumatoid arthritis (RA)

    Patients with RA meeting the classification criteria of American College of Rheumatology (ACR) and/or European League Against Rheumatism (EULAR) från 2010.

    Other: Care as usual

  • Patients with psoriatic arthritis (PsA)

    Patients with PsA meeting the classification criteria of Classification for Psoriatic Arthritis (CASPAR).

    Other: Care as usual

  • Patients with undifferentiated arthritis

    Defined as a patients with a clear arthritis, but not meeting with established classifications criteria of any now known rheumatic disease.

    Other: Care as usual

  • Patients with psoriasis

    Patients with psoriasis diagnosed at a dermatology department. The patients should not have any history of joint complaints with a duration of more than 6 weeks.

    Other: Care as usual

  • General population controls

    General population controls retrieved from the Population Register, matched for age, sex and residence of living to the included patients.

Interventions

  • OtherCare as usual

    No intervention will be given. The study will follow the effects of care as usual.

06

What researchers measure

Primary outcomes

  1. Disease activity

    Disease Activity Score using 28 joint counts (DAS28) score range 0-9.07

    Time frame: 12 months

07

Study locations

1 site
  • Clinical Rheumatology Research Center (CRRC), Department of Rheumatology, Sahlgrenska University Hospital
    Gothenburg, 413 45, Sweden
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Dec 2039, 239 months after the start.

Of 235 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 239 months is above that.

Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2019
First posted
Dec 9, 2019
StartActual
Jan 1, 2020
Primary completionEst.
Dec 31, 2039
CompletionEst.
Dec 21, 2069
Last update
Oct 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04190758
Responsible party
Sponsor
First posted
Dec 9, 2019
Start date
Jan 1, 2020
Primary completion
Dec 31, 2039 (estimated)
Completion
Dec 21, 2069 (estimated)
Last update
Oct 12, 2021

Study contacts

Eva Klingberg, Assoc. Prof
principal investigator · Dep of Rheumatology and Inflammation research, University of Gothenburg, Sweden
Inger Gjertsson, Prof
principal investigator · Dep of Rheumatology and Inflammation research, University of Gothenburg, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion